Who are Qiv's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quadrivalent Influenza Vaccine, DTacP-IPV combined vaccine (TETRAXIM™), Trivalent Inactivated Vaccine, Seasonal Inactivated Influenza Vaccine, GamEvac-Combi (vaccine), REPEVAX® after REVAXIS®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/qiv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Qiv — Competitive Intelligence Brief

Qiv (qiv) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated vaccine. Area: Immunology.

marketed Inactivated vaccine Influenza viruses Immunology Live · refreshed every 30 min

Target snapshot

Qiv (qiv) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Qiv TARGET	qiv	Pfizer	marketed	Inactivated vaccine	Influenza viruses
Quadrivalent Influenza Vaccine	Quadrivalent Influenza Vaccine	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Inactivated vaccine	Influenza viruses
DTacP-IPV combined vaccine (TETRAXIM™)	DTacP-IPV combined vaccine (TETRAXIM™)	Sanofi	marketed	Combination inactivated vaccine	Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3
Trivalent Inactivated Vaccine	Trivalent Inactivated Vaccine	McMaster University	marketed	Inactivated vaccine
Seasonal Inactivated Influenza Vaccine	Seasonal Inactivated Influenza Vaccine	Pfizer	marketed	Inactivated vaccine
GamEvac-Combi (vaccine)	GamEvac-Combi (vaccine)	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	marketed	Combination inactivated vaccine
REPEVAX® after REVAXIS®	REPEVAX® after REVAXIS®	Sanofi Pasteur, a Sanofi Company	phase 3	inactivated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated vaccine class)

Pfizer · 3 drugs in this class
McMaster University · 1 drug in this class
Sanofi Pasteur, a Sanofi Company · 1 drug in this class
Sinovac Biotech Co., Ltd · 1 drug in this class
St. Petersburg Research Institute of Vaccines and Sera · 1 drug in this class
The University of Hong Kong · 1 drug in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 1 drug in this class
Vac4All · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Qiv — Competitive Intelligence Brief. https://druglandscape.com/ci/qiv. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab